| Literature DB >> 31434526 |
Anna-Maria Krooupa1, Bella Vivat1, Stephen McKeever1,2, Elena Marcus1, Joseph Sawyer1, Paddy Stone1.
Abstract
BACKGROUND: The use of observational measures to assess palliative care patients' level of consciousness may improve patient care and comfort. However, there is limited knowledge regarding the validity and reliability of these measures in palliative care settings. AIM: To identify and evaluate the psychometric performance of observational level of consciousness measures used in palliative care.Entities:
Keywords: Analgesics; consciousness; hypnotics and sedatives; palliative care; psychometrics; surveys and questionnaires; systematic review; terminal care
Mesh:
Substances:
Year: 2019 PMID: 31434526 PMCID: PMC6952953 DOI: 10.1177/0269216319871666
Source DB: PubMed Journal: Palliat Med ISSN: 0269-2163 Impact factor: 5.713
Search strategy and eligibility criteria.
| Search strategy | Step 1: broad search of relevant literature | 1. Identification of relevant publications in PsycINFO and
MEDLINE |
| Step 2: Systematic database search | Databases: | |
| Dates: | ||
| Restrictions: | ||
| Search terms (used in MEDLINE and modified for other
databases): | ||
| Step 3: Citation searching | (1) Backward citation searching (hand-searching reference lists of included publications) and (2) forward citation searching (hand-searching studies citing included publications through Google Scholar) were repeated until no more relevant publications could be located | |
| Step 4: Contacting authors | 1. Authors of conference abstracts meeting inclusion
criteria contacted for full-text publications | |
| Eligibility criteria | Inclusion criteria | 1. Primary research studies |
| Exclusion criteria | 1. Non-primary studies, including systematic
reviews |
CENTRAL: Cochrane Central Register of Controlled Trials; CINAHL: Cumulative Index to Nursing and Allied Health Literature; WoS: Web of Science.
Quality criteria for measure appraisal.
| Domain | Property | Score | Description |
|---|---|---|---|
| Number of participants | 2 | ||
| 1 | 50 < | ||
| 0 | |||
| Validity | Content validity | 2 | A description of the construct that is being measured is provided and target population is involved in item selection |
| 1 | A description of the construct that is being measured is provided or target population is involved in item selection | ||
| 0 | The construct that is being measured is not described and limited/no involvement of target population in item selection | ||
| Criterion validity | 2 | Correlates acceptable to high ( | |
| 1 | Correlates moderate–acceptable
(0.40 < | ||
| 0 | Correlates low ( | ||
| Structural validity | 2 | Appropriate method of factor analysis performed and factors account for ⩾50% of the total variance | |
| 1 | Factor analysis performed but another method would have been more appropriate | ||
| 0 | Factors account for <50% of the total variance | ||
| Construct validity | 2 | Correlates with other level of consciousness measures
acceptable to high ( | |
| 1 | Correlates with other level of consciousness measures are
moderate (0.40 < | ||
| 0 | Correlates with other level of consciousness measures are
low ( | ||
| Reliability | Homogeneity (internal consistency) | 2 | 0.70 < alpha < 0.90 |
| 1 | Alpha > 0.90 or 0.60 < alpha < 0.70 | ||
| 0 | Alpha < 0.60 | ||
| Inter-rater reliability | 2 | Reliability coefficient > 0.80 | |
| 1 | 0.60 < reliability coefficient < 0.80 | ||
| 0 | Reliability coefficient < 0.60 | ||
| Intra-rater and/or test–retest reliability | 2 | Reliability coefficient > 0.80 | |
| 1 | 0.60 < reliability coefficient < 0.80 | ||
| 0 | Reliability coefficient < 0.60 | ||
| Responsiveness | 2 | Appropriate method of detecting clinically meaningful change over time described and clinically meaningful change over time detected and 15% or less of respondents achieved the lowest or highest possible score, respectively | |
| 1 | Appropriate method of detecting clinically meaningful change over time described and clinically meaningful change over time detected or 15% or less of respondents achieved the lowest or highest possible score, respectively | ||
| 0 | Appropriate method of detecting clinically meaningful change over time not followed or clinically meaningful change over time not detected or more than 15% of the respondents achieved the lowest or highest possible score, respectively | ||
| Origin of items | 2 | Items specifically developed for use with palliative care patients | |
| 1 | Items were modified for use with palliative care patients | ||
| 0 | Items originated from a scale developed for another population | ||
| Feasibility | 2 | Scale is short, manageable with instructions, scoring interpretation | |
| 1 | Scale is manageable (one format) | ||
| 0 | Scale is more complex |
Figure 1.PRISMA flow diagram of study selection process.[24]
CENTRAL: Cochrane Central Register of Controlled Trials; CINAHL: Cumulative Index to Nursing and Allied Health Literature; WoS: Web of Science.
Description of identified studies and measures.
| Author | Study aim | Study setting | Study population | Measure name/acronym | Purpose of measure | Subscales/number of items | Response options |
|---|---|---|---|---|---|---|---|
| Studies reporting | |||||||
| Abernethy et al.[ | To determine the efficacy of oral morphine for the management of refractory dyspnoea | Palliative, general, respiratory, cardiac medicine clinics | 48 outpatients with refractory dyspnoea | – | To measure sedation depth as a side effect of morphine use | S: – | 4-level scale (‘No’, ‘Mild’, ‘Moderate’, ‘Severe’ sedation) |
| Aretha et al.[ | Evaluation of patient/family-controlled sedation with midazolam for intractable symptom control | Tertiary care university hospital | 8 terminal cancer inpatients | – | Monitoring of patients after terminal sedation initiation | S: – | 4-point scale (1 = ‘Awake’, 2 = ‘Arousable with voice’, 3 = ‘Arousable with light pain’, 4 = ‘Unarousable’) |
| Arevalo et al.[ | To describe nurses’ experiences with the decision-making and performance of CPS | Home care organisations, palliative care units (based in nursing homes or inpatient hospices), hospitals | 199 nurses reporting on their last patient receiving CPS | – | Monitoring of CPS | S: – | 6-level scale (‘Drowsiness’, ‘Eyes closed, reaction to verbal stimuli’, ‘Eyes closed, reaction to physical stimuli’, ‘Eyes closed, no reaction to physical stimuli’, ‘Other’, ‘I don’t know’) |
| Barbato[ | Exploration of the clinical application of BIS monitoring in palliative care | Hospice | 12 unconscious palliative care inpatients | Consciousness Scale (modified GCS)[ | Monitoring of consciousness level from the onset of unconsciousness and until death | S: 6 (breathing, movement, pulse volume, eyelash reflex,
peripheries and response to name call) | 4-point scale (1–4) for each subscale. Scores can be calculated per subscale and as a total score. |
| Baumann et al.[ | Evaluation of the safety and efficacy of patient-controlled analgesia in patients with unsuccessfully treated chronic pain secondary to cancer | Not specified | 8 terminally ill cancer patient | – | To evaluate sedation for the assessment of individual analgesic response | S: – | 5-point scale (1 = ‘Wide awake’, 2 = ‘Drowsy’, 3 = ‘Dozing intermittently’, 4 = ‘Mostly sleeping’, 5 = ‘Only awakens when aroused’) |
| Dean et al.[ | Description of PS decision-making practices in a UK hospice over the course of five years | Hospice | 234 patient charts | Sedation scale (modified RASS)[ | Accessing level of sedation to guide PS clinical decision-making and documentation | S: – | 6-point scale (+2 = ‘Agitated/Distressed’, +1 = ‘Anxious/Restless’, 0 = ‘Alert, orientated, calm’, –1 = ‘Drowsy: Opening eyes and establishing eye contact for periods of 10 seconds or more, responds to commands’, –2 = ‘Moderate sedation: Rousable to voice or physical stimulation. Unable to communicate’, –3 = ‘Deep sedation: Unrousable’) |
| Fainsinger et al.[ | To provide a better understanding of the use of sedation for the management of uncontrolled symptoms in terminally ill patients | Hospices and hospital-based palliative care unit | 387 palliative care patient | – | To assess level of consciousness after initiation of sedation for uncontrolled symptoms | S: – | 3-level scale (‘Alert’, ‘Drowsy’, ‘Unresponsive’) |
| Hendriks et al.[ | To investigate symptoms, treatment and quality of life in patients with end-stage dementia | Nursing homes | 330 end-stage dementia patients (213 recruited on admission, 117 retrospectively) | – | To assess the level of consciousness that most frequently occurred during the last week of life | S: – | 6-level scale (‘Awake and alert’, ‘Awake’, ‘Awake but drowsy looking’, ‘Falling asleep’, ‘Light sleep’, ‘Deep looking sleep’) |
| Jaspers et al.[ | Description of the practice of PS in Germany | Palliative care units, inpatient hospices | 1944 electronic patient records | – | To assess depth of PS | S: – | 3-level scale (‘Somnolence’, ‘Stupor’, ‘Coma’) |
| Morita et al.[ | To investigate the change in physical signs and medical interventions in the dying process | Palliative care unit | 100 terminally ill cancer patient | Categorical scale (modified Riker Sedation–Agitation Scale[ | To examine changes in the level of consciousness in the last four weeks of life | S: – | 4-level scale (‘Awake: arousable, follows commands’, ‘Drowsy: difficult to arouse or unable to attend to conversation or commands’, ‘Very drowsy: awakens to noxious stimuli only’, ‘Coma: does not awaken to any stimuli’) |
| Morita et al.[ | Identification of risk factors for the development and persistency of death rattle | Palliative care unit | 245 terminally ill cancer patients (of whom 107 developed death rattle) | Categorical scale (modified Riker Sedation–Agitation Scale)[ | To assess conscious level as a risk factor for the development/persistency of death rattle | Same as above | Same as above |
| Morita et al.[ | To investigate the effects of partial opioid substitution and hydration on the occurrence of agitated delirium in the final stage of cancer | Palliative care unit | 284 terminally ill cancer inpatient charts | Fainsinger’s consciousness scale ( | Evaluation of consciousness level as part of the assessment of the degree of cognitive impairment | S: – | 3-level scale (‘Alert’, ‘Drowsy’, ‘Unresponsive’) |
| Morita et al.[ | To establish the communication capacity level and identify factors contributing to communication capacity impairment and agitated delirium in cancer patients in their final week of life | Palliative care unit | 284 terminally ill cancer inpatient charts | Fainsinger’s consciousness scale ( | Evaluation of consciousness level in the last week of life | Same as above | Same as above |
| Papavasiliou et al.[ | To compare physician-reported practices on CDSUD between general practitioner and medical specialists | Not specified | 561 cases of CDSUD reported by physicians | – | Level of unconsciousness (comatose) used to assess the degree of patients’ awareness during the practice of CDSUD | S: – | 11-point scale |
| Pasman et al.[ | To study the level and course of discomfort, and factors that are associated with discomfort in patients with dementia for whom artificial nutrition and hydration are forgone | Nursing homes | 178 patients with severe dementia | – | To assess the level of consciousness as a determinant of discomfort | S: – | 6-point scale (response options not described) |
| Portenoy et al.[ | Exploration of the relationship between opioid use and survival at the end of life | Hospices | 725 palliative care inpatients | – | Level of consciousness at the time of last opioid dose change assessed for its association with length of survival | S: – | 4-level scale (‘Full level of consciousness’, ‘Drowsy’, ‘Confused’, ‘Unable to respond’) |
| Rys et al.[ | Investigation of the practice of CSD in nursing homes | Nursing homes | 249 nurse reports of their most recent patient treated with CSD | – | To assess depth of sedation reached after the administration of CSD | S: – | 5-level scale |
| Swart et al.[ | Description of the practice of CPS until death after the introduction of a national palliative guideline | Not specified | 370 physicians providing information about their last patient who received CPS until death | – | To assess depth of continuous sedation reached after the administration of CPS until death | S: – | 5-point scale (‘Drowsy’, ‘Eyes closed, responding promptly to verbal command’, ‘Eyes closed, arousable only by physical stimuli’, ‘Eyes closed, not arousable by physical stimuli’, ‘Other’) |
| Van Deijck et al.[ | Investigation of the practice of CPS in elderly patients | Nursing homes | 316 nursing home physicians reporting on their last case of CPS | – | Evaluation of level of consciousness at adequate symptom relief after the administration of CPS | S: – | 6-level scale |
| Van Deijck et al.[ | To explore the characteristics of patients with existential suffering treated with CPS and the degree to which preconditions for administering CPS are fulfilled | Nursing homes | 314 cases of patients who received CPS described by nursing home physicians | – | Evaluation of level of consciousness at adequate symptom relief after the administration of CPS | Same as above | Same as above |
| Van Der Steen et al.[ | To compare discomfort in dementia patients dying from pneumonia with patients dying after intake problems, and to assess associations with treatment | Nursing homes | 725 end-stage dementia patients | – | To explore the association between level of consciousness and discomfort | S: – | 6-level scale (‘Awake and alert’, ‘Awake’, ‘Awake but drowsy looking’, ‘Falling asleep’, ‘Light sleep’, ‘Deep looking sleep’) |
| Studies reporting established measures | |||||||
| Agar et al.[ | To determine the efficacy of risperidone or haloperidol relative to placebo for delirium symptoms among palliative care patients | Hospice and hospital palliative care inpatient services | 247 palliative care inpatients with various diagnoses; predominantly cancer | RASS[ | To measure sedation as an adverse effect of risperidone/haloperidol use | S: – | 10-point scale (+4 = ‘Combative’, +3 = ‘Very agitation’, +2 = ‘Agitated’, +1 = ‘Restless’, 0 = ‘Alert and Calm’, –1 = ‘Drowsy’, –2 = ‘Light sedation’, –3 = ‘Moderate sedation’, –4 = ‘Deep sedation’, –5 = ‘Unarousable’) |
| Alonso-Babarro et al.[ | Assessment of the incidence and efficacy of PS for patients who died at home | Home | 245 terminally ill cancer patient records | RSS[ | To monitor level of sedation after administration of PS | S: – | 6-point scale (1 = ‘Anxious and agitated or restless or both’, 2 = ‘Co-operative, orientated and tranquil, 3 = ‘Responds to commands only’, 4 = ‘Brisk response to a light glabellar tap or loud auditory stimulus, 5 = ‘Sluggish response’, 6 = ‘No response’) |
| Barbato et al.[ | To determine the validity of the BIS monitor and two observational scales | Palliative care unit | 40 unresponsive palliative care inpatients | RASS[ | To assess level of sedation for the exploration of the association with BIS values | Same as above | Same as above |
| Barbato et al.[ | To examine the effectiveness of breakthrough medication in unresponsive patients and the perception of patient comfort made by nurses and family | Palliative care unit | 40 unresponsive palliative care inpatients | RASS[ | To measure level of sedation for the assessment of the effect of breakthrough opioid/benzodiazepine use | Same as above | Same as above |
| Benitez-Rosario et al.[ | To assess the feasibility of a quality care project in PS | Hospital-based palliative care service | 204 patient charts | RASS[ | To assess the level of deep continuous sedation with the aim to reach a predetermined level (–5 RASS for patients with continuous dyspnoea at rest; –4 RASS for delirium or other reasons) | Same as above | Same as above |
| Boyd and Kelly[ | Evaluation of the effectiveness of oral morphine for the symptomatic treatment of dyspnoea in patients with advanced cancer | Home, hospice | 15 advanced cancer patients with dyspnoea | VAS | To measure sedation as a side effect of oral morphine | S: – | 100 mm line anchored by two verbal descriptors; 0: ‘Fully awake’, 100: ‘Asleep’ |
| Campbell et al.[ | To investigate the self-reporting of dyspnoea at the very end of life | Palliative care unit | 89 palliative care inpatients at the risk of experiencing dyspnoea | RLS85[ | To assess consciousness as patient characteristic for the exploration of the association with the ability to self-report dyspnoea symptoms | S: – | 8-point scale (1 = ‘Alert; No delay in response’, 2 = ‘Drowsy or confused; Responsive to light stimulation’, 3 = ‘Very drowsy or confused; Responsive to strong stimulation’ 4 = ‘Unconscious; Localizes but does not ward off pain’, 5 = ‘Unconscious; Withdrawing movement on pain stimulation’, ‘6 = Unconscious; Stereotype flexion movements on pain stimulation’, 7 = ‘Unconscious; Stereotype extension movements on pain stimulation’, 8 = ‘Unconscious; No response to pain stimulation’) |
| Campbell et al.[ | To establish the reliability and construct validity of a revised RDOS | Palliative care unit | 89 palliative care inpatients at the risk of experiencing dyspnoea | RLS85[ | To assess consciousness for ascertaining the construct validity of RDOS | Same as above | Same as above |
| Campbell et al.[ | To determine the effect of oxygen administration at the very end of life | Hospice, hospital-based palliative care service | 32 hospice and hospital inpatients at the very end of life | RLS85[ | To measure consciousness for the correlation with respiratory distress and nearness to death | Same as above | Same as above |
| Campbell et al.[ | Determination of the trajectory of dyspnoea and respiratory distress | Hospice | 91 home-based palliative care patients | RLS85[ | To measure consciousness for the correlation with respiratory distress and nearness to death | Same as above | Same as above |
| Caraceni et al.[ | Comparison of PS practices in home care and hospice settings | Home-based palliative care services, hospices | 531 terminal cancer patients receiving PS | MWSS[ | Level of consciousness assessed as part of the PS monitoring process | S: – | 5-point scale (1 = ‘Fully awake and oriented’, 2 = ‘Drowsy but rousable’, 3 = ‘Eyes closed but rousable to command’, 4 = ‘Eyes closed but rousable to mild physical stimulation (earlobe tug)’, 5 = ‘Eyes closed but unrousable to mild physical stimulation’) |
| De la Cruz et al.[ | To describe the prevalence and severity of symptoms, including delirium, in the final week of life and evaluate the usefulness of the Nursing Delirium Screening Scale | Hospice | 78 terminally ill cancer patients | RASS[ | To measure sedation or agitation as the predominant features of delirium | Same as above | Same as above |
| Franken et al.[ | To evaluate the variability in response to midazolam and to find clinically significant covariates that predict pharmacodynamic response | Palliative care centre | 43 terminally ill inpatients receiving midazolam | RSS[ | To measure the effect of midazolam on patients’ sedation level | Same as above | Same as above |
| Goncalves et al.[ | Description of the sedation practice of Portuguese palliative care teams | Palliative care inpatient, home care, hospital support care services | 181 palliative care patients (of whom 27 received sedation) | CSPC[ | To assess the deepest consciousness level reached after the administration of sedation | S: – | 6-point scale (1 = ‘Awake’, 2 = ‘Awakens when called by name and stays awake during discussion’, 3 = ‘Awakens but falls asleep during discussion’, 4 = ‘Reacts with movement/brief eye opening, but without eye contact, when called by name’, 5 = ‘Reacts to trapezius muscle pinching’, 6 =’Does not react’) |
| Goncalves et al.[ | To examine the activity of Portuguese palliative care teams | Inpatient, home care and hospital palliative care support care services | 164 palliative care patients | CSPC[ | Evaluation of consciousness level as a patient characteristic | Same as above | Same as above |
| Ferraz Goncalves et al.[ | Comparison of haloperidol alone and in combination with midazolam for the treatment of acute agitation in palliative care | Palliative care unit | 79 palliative care inpatients | CSPC[ | To assess level of consciousness when control of agitation is reached | Same as above | Same as above |
| Hsu et al.[ | To investigate the characteristics and outcomes of non-cancer palliative care patients in an acute general care setting | Acute general medicine ward | 258 inpatients (of whom 193 did not meet criteria for cancer palliative care) | GCS[ | To measure GCS score as a clinical characteristic for the comparison between cancer and non-cancer patients | S: 3 (motor response, verbal response, eye opening) | Eye opening: 4-point scale (1–4), Motor response: 6-point scale (1–6), Verbal response: 5-point scale (1–5) |
| Hui et al.[ | To examine the frequency and onset of bedside physical signs and their diagnostic performance for impending death | Acute palliative care units | 357 advanced cancer inpatients | RASS[ | Decreased level of consciousness (RASS ⩽ –2) assessed as a clinical sign of impending death | Same as above | Same as above |
| Hui et al.[ | To compare the effect of lorazepam versus placebo as adjuvant to haloperidol for persistent agitation | Acute palliative care unit | 93 advanced cancer inpatients with agitated delirium | RASS[ | To measure sedation and agitation for the evaluation of the effect of pharmacological interventions for the treatment of agitation | Same as above | Same as above |
| Hwang et al.[ | To determine the events that herald the onset of dying process and evaluate their predictive value for death within 48 hours | Palliative care unit | 181 terminal cancer inpatients | AVPU[ | To measure conscious level as clinical sign of impending death | S: – | 4-level scale (A = ‘Eyes opened spontaneously, orientated speech, obeys commands, V = ‘Any verbal, motor, or eye response to verbal stimulus’, P = ‘Any verbal, motor, or eye response to painful stimulus’, U = ‘Unresponsive to any stimulus’) |
| Imai et al.[ | To investigate the effect of two types of PS therapy: proportional and deep sedation | Palliative care unit | 50 cancer inpatients | Modified RASS[ | To define deep sedation (RASS ⩾ –4) and the absence of agitation (RASS ⩽ 0) | S: – | 10-point scale (+4 = ‘Combative’ to
−5 = ‘Unarousable’) |
| Klepstad et al.[ | Investigation of the relationship between patient self-reports of CF and sedation with objective assessments of CF and sedation | Hospital-based palliative care unit | 29 cancer inpatients | OAA/S[ | To objectively assess sedation and compare scores with patient self-reports | S: 4 (responsiveness, speech, facial expression, eyes) | Responsiveness: 5-point scale (1–5), Speech: 4-point scale (2–5), Facial expression: 3-point scale (3–5), Eyes: 3-point scale (3–5) |
| Kohara et al.[ | Investigation of the influence of sedative drugs on consciousness | Hospital-based palliative care unit | 124 terminally ill cancer inpatients (of whom 63 received sedation) | Communication Capacity Scale–Item 1 (Conscious level)[ | To compare level of consciousness between sedated and unsedated patients | S: – | 6-point scale (0 = ‘Awake with no drowsiness’ to 5 = ‘Cannot remain awake and cannot be awakened by physical stimuli’) |
| Maltoni et al.[ | Evaluation of the practice of PS in two Italian hospices | Hospice | 327 inpatients (of whom 72 received PS) | RASS[ | RASS scores used for monitoring PS (negativisation of scores proxy indicator of the efficacy of PS) | Same as above | Same as above |
| Masman et al.[ | To determine the feasibility and validity of BIS monitoring in terminally ill patients | Palliative care centre | 58 terminally ill inpatients | RSS[ | To assess level of sedation and evaluate the correlation between Ramsay scores and BIS values | Same as above | Same as above |
| Matsunuma et al.[ | Evaluation of the signs, symptoms and treatments of patients with ILD before death | Community hospital | 82 end-stage ILD and lung cancer inpatient records | JCS[ | To determine the frequency of loss of consciousness (defined as more than 1 point on JCS) before death and examine its causes | S: – | 10-point scale (One level (0) for ‘fully conscious’, 3 levels (1–3) for the patient who is ‘awake without any stimuli’, 3 levels (10–30) for the patient who ‘can be aroused after stimulation’, 3 levels (100–300) for the patient who ‘cannot be aroused with any forceful mechanical stimuli’) |
| McMillan and Tittle[ | To describe cancer and palliative care patients’ pain, pain-related side effects and the nurses’ assessment and responses to these | Cancer centre, hospice home care service | 44 patients treated for pain | Sedation Item of the Pain Flow Sheet[ | To evaluate level of sedation as a opioid-induced side effect | S: – | 5-point scale (0 = ‘Fully alert’, 1 = ‘Relaxed, awake’, 2 = ‘Drowsy, dozing’, 3 = ‘Arousable sleep’, 4 = ‘Comatose’) |
| Mercadante et al.[ | Assessment of the need and the effectiveness of sedation for intractable symptoms, and the thoughts of relatives regarding sedation | Acute pain relief and palliative care unit | 77 terminally ill cancer patient (of whom 42 received sedation) | Communication Capacity Scale–Item 1 (Conscious level)[ | To assess patients’ level of sedation after the initiation of PS | Same as above | Same as above |
| Mercadante et al.[ | To assess the attitudes of palliative care clinicians regarding PS at home | Home | 150 physicians involved in end of life care decisions | RASS[ | Monitoring of PS | RASS:[ | RASS:[ |
| Mercadante et al.[ | To assess the efficacy of hyoscine butylbromide for the management of death rattle | Hospices | 132 cancer inpatients with reduced level of consciousness | RASS-PAL[ | Identification of patients with reduced level of consciousness (RASS-PAL ⩽ –3) | S: – | 10-point scale (+4 = ‘Combative’ to
−5 = ‘Unarousable’) |
| Monreal-Carrillo et al.[ | Characterisation of the level of consciousness of patients undergoing PS using BIS monitoring | Palliative care unit | 20 advanced cancer inpatients receiving PS | RSS[ | Assessment of sedation level after initiation of PS | Same as above | Same as above |
| Morita et al.[ | Development and validation of the Communication Capacity Scale and the Agitation Distress scale | Palliative care unit based in a cancer institute | 30 terminally ill cancer inpatients with delirium | Communication Capacity Scale–Item 1 (Conscious level)[ | To test the association between Communication Capacity scores and Sedation Scale scores | -Communication Capacity Scale–Item 1 (Conscious level):[ | Communication Capacity Scale–Item 1 (Conscious level):[ |
| Palacio et al.[ | Description of the practice of PS | Specialised palliative care unit based in a cancer institute | 66 advanced cancer inpatients undergoing PS | RSS[ | Assessment of sedation level after initiation of PS | Same as above | Same as above |
| Porzio et al.[ | Evaluation of the feasibility and efficacy of PS at home | Home care service | 16 terminally ill cancer home patient charts | RSS[ | To monitor the level of sedation after the administration of PS with the aim to reach deep, continuous sedation (RSS ⩾ 5) | Same as above | Same as above |
| Pype et al.[ | To explore the practice of suboptimal PS in primary care | Home | Seven palliative care home teams and 7 general practitioners reporting on 27 cases of PS | RASS[ | To measure depth of sedation throughout the procedure of PS | Same as above | Same as above |
| Schmitz et al.[ | To investigate the effectiveness of intravenous opioid PCT in reducing breathlessness in patients with advanced malignant disease | Palliative care centre | 18 patients with moderate or severe breathlessness | RASS[ | To monitor changes in sedation and agitation levels after PCT onset | Same as above | Same as above |
| Van Deijck et al.[ | To explore which patient-related factors at admission are associated with receiving CPS in the terminal phase of life | Hospices, nursing home-based palliative care units | 467 palliative care inpatients (of whom 130 received CPS) | GCS[ | To evaluate the level of consciousness on admission as a patient-related characteristic and examine its association with CPS | Same as above | Same as above |
| Studies reporting measure psychometric properties | |||||||
| Arevalo et al.[ | To study the reliability and validity of observer-based sedation scales in PS | Hospices, nursing home | 54 inpatients receiving PS | MSAT[ | To assess the level of consciousness before and during the course of PS | MSAT:[ | MSAT:[ |
| Benitez-Rosario et al.[ | To test the appropriateness and reliability of the RASS in Spanish patients with advanced cancer | Palliative care unit | 156 advanced cancer inpatients | Modified RASS[ | To monitor sedation and agitation | Same as above | Same as above |
| Bush et al.[ | Exploration of the validity and feasibility of a version of the RASS modified for palliative care populations | Acute palliative care unit | 10 inpatients with agitated delirium or receiving PS | RASS-PAL[ | To assess the level of sedation and agitation | Same as above | Same as above |
| Claessens et al.[ | Description of the characteristics of palliative care patients receiving sedation for the management of refractory symptoms | Palliative care units | 266 terminally ill cancer inpatients (of whom 20 received PS) | GCS[ | Evaluation of level of consciousness at the start and during PS | S: 3 (motor response, verbal response, eye opening) | Eye opening: 4-point scale (1–4), Motor response: 6-point scale (1–6), Verbal response: 5-point scale (1–5) |
| Claessens et al.[ | To examine the impact of PS on the level of consciousness of terminally ill patients | Palliative care units | 266 terminally ill cancer inpatients (of whom 20 received PS) | GCS[ | Evaluation of level of consciousness with the aim to assess the effect of PS | Same as above | Same as above |
| Claessens et al.[ | Description of the effect of PS on oral and/or artificial food and fluid intake in terminally ill patients | Palliative care units | 266 terminally ill cancer inpatients (of whom 20 received PS) | GCS[ | To evaluate patients’ level of consciousness at admission | Same as above | Same as above |
| Goncalves et al.[ | Validation of a consciousness scale for palliative care | Palliative care unit | 38 advanced cancer inpatients | CSPC[ | To assess level of consciousness | S: – | 6-point scale (1 = ‘Awake’, 2 = ‘Awakens when called by name and stays awake during discussion’, 3 = ‘Awakens but falls asleep during discussion’, 4 = ‘Reacts with movement/brief eye opening, but without eye contact, when called by name’, 5 = ‘Reacts to trapezius muscle pinching’, 6 =’Does not react’) |
CPS: continuous palliative sedation; BIS: bispectral index; GCS: Glasgow Coma Scale; PS: palliative sedation; RASS: Richmond Agitation–Sedation Scale; CDSUD: continuous deep sedation until death; CSD: continuous sedation until death; RSS: Ramsay Sedation Scale; VAS: visual analogue scale; RLS85: Reaction Level Scale 85; RDOS: Respiratory Distress Observation Scale; MWSS: Modified Wilson Sedation Scale; CSPC: Consciousness Scale for Palliative Care; AVPU: Alert/Verbal/Painful/Unresponsive Scale; CF: cognitive function; OAA/S: Observer’s Assessment of Alertness/Sedation; ILD: interstitial lung disease; JCS: Japan Coma Scale; RASS-PAL: Richmond Agitation–Sedation Scale–Palliative version; PCT: patient-controlled therapy; MSAT: Minnesota Sedation Assessment Tool; VICS: Vancouver Interaction and Calmness Scale; KNMG: Sedation score proposed in the Guideline for Palliative Sedation of the Royal Dutch Medical Association.
Figure 2.Number of identified studies and measures by instrument category.
Appraisal of psychometric performance of observational level of consciousness measures.
| Measure and studies | Number of participants | Content validity | Criterion validity | Structural validity | Construct validity | Homogeneity (internal consistency) | Inter-rater reliability | Intra-rater and/or test–retest reliability | Responsiveness | Origin of items | Feasibility |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MSAT (Dutch version) | Description of construct provided. No involvement of target population in item selection | Gold standard not available | NE/NR | Assessed per subscale | NE/NR | Assessed per subscale | NE/NR | NE/NR | Items originated from a scale developed for another population | Evaluated as clear and easy to use (when compared with the Dutch versions of RASS and VICS) | |
| Rating | 1 | 1 | – | – | MSATa: 2 | – | MSATa: 1 | – | – | 0 | 2 |
| VICS (Dutch version) | Description of construct provided. No involvement of target population in item selection | Gold standard not available | NE/NR | Assessed per subscale | NE/NR | Assessed per subscale | NE/NR | NE/NR | Items originated from a scale developed for another population | Evaluated as the least clear and easy to use (when compared with the Dutch versions of RASS and MSAT) | |
| Rating | 1 | 1 | – | – | VICSi: 1 | – | VICSi: 2 | – | – | 0 | 1 |
| RASS (Dutch version) | Description of construct provided. No involvement of target population in item selection | Gold standard not available | NE/NR | Spearman’s correlation coefficient ranged from 0.57 to 0.84 | NE/NR | ICC ranged from 0.71 (95% CI: 0.60 to 0.79) to 0.73 (95% CI: 0.58 to 0.83) depending on time difference between paired assessments | NE/NR | NE/NR | Items originated from a scale developed for another population | Evaluated as the least time-consuming, clearest and easiest to use (when compared with Dutch MSAT and VICS) | |
| Rating | 1 | 1 | – | – | 2 | – | 1 | – | – | 0 | 2 |
| KNMG | Description of construct provided. No involvement of target population in item selection | Gold standard not available | NE/NR | Spearman’s correlation coefficient ranged from 0.44 to 0.84 | NE/NR | ICC ranged from 0.66 (95% CI: 0.54 to 0.76) to 0.71 (95% CI: 0.55 to 0.82) depending on time difference between paired assessments | NE/NR | NE/NR | Measure specifically developed for use with palliative care patients | NE/NR | |
| Rating | 1 | 1 | – | – | 2 | – | 1 | – | – | 2 |
|
| Modified RASS | Description of construct provided. Target population involved in item modification | Gold standard not available | NE/NR | Spearman’s correlation coefficient ranged from 0.81 to 0.89
( | NE/NR | Weighted Cohen’s kappa ranged from 0.85 (95% CI: 0.85 to 0.92) to 0.95 (95% CI: 0.91 to 0.98) | NE/NR | Not adequate information provided | Items modified for use with palliative care patients | Reported as a very useful, manageable tool that could facilitate fluid communication among the palliative care team | |
| Rating | 2 | 2 | – | – | 2 | – | 2 | – | – | 1 | 2 |
| RASS-PAL | Description of construct provided. Target population involved in item modification | Gold standard not available | NE/NR | NE/NR | NE/NR | ICC ranged from 0.84 (95% CI: 0.56 to 0.95) to 0.98 (95% CI: 0.95 to 1.00) | NE/NR | NE/NR | Items modified for use with palliative care patients | Evaluated as easy to use, simple and brief | |
| Rating | 0 | 2 | – | – | – | – | 2 | – | – | 1 | 2 |
| GCS (Dutch version) | Description of construct provided. No involvement of target population in item selection | Gold standard not available | NE/NR | NE/NR | NE/NR | ICC = 0.807 (CI = 0.671–0.891;
| NE/NR | NE/NR | Items originated from a scale developed for another population | NE/NR | |
| Rating | 2 | 1 | – | – | – | – | 2 | – | – | 0 | – |
| CSPC | Description of construct provided. Target population involved in item selection | Gold standard not available | NE/NR | Spearman’s correlation coefficient ranged from 0.82 to 0.95
( | Cronbach’s | ICC = 0.99 ( | NE/NR | NE/NR | Scale specifically developed for use with palliative care patients | Evaluated as easy to use and useful in clinical practice | |
| Rating | 0 | 2 | – | – | 2 | 2 | 2 | – | – | 2 | 2 |
MSAT: Minnesota Sedation Assessment Tool; NE: not evaluated; NR: not reported; MSATa: Minnesota Sedation Assessment Tool arousal subscale; ICC: intraclass correlation coefficient; CI: confidence interval; MSATm: Minnesota Sedation Assessment Tool motor activity subscale; MSATq: Minnesota Sedation Assessment Tool quality of sedation subscale; RASS: Richmond Agitation–Sedation Scale; VICS: Vancouver Interaction and Calmness Scale; VICSi: Vancouver Interaction and Calmness Scale interaction subscale; VICSc: Vancouver Interaction and Calmness Scale calmness subscale; KNMG: Sedation score proposed in the Guideline for Palliative Sedation of the Royal Dutch Medical Association; RASS-PAL: Richmond Agitation–Sedation Scale–Palliative version; GCS: Glasgow Coma Scale; CSPC: Consciousness Scale for Palliative Care.